WCBA
UTHR icon

Weaver C. Barksdale & Associates’s United Therapeutics UTHR Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$10K Sell
68
-3
-4% -$381 0.01% 279
2017
Q3 		$8K Buy
71
+5
+8% +$639 0.01% 319
2017
Q2 		$9K Hold
66
– – 0.01% 289
2017
Q1 		$9K Hold
66
– – 0.01% 299
2016
Q4 		$9K Buy
66
+5
+8% +$638 0.01% 300
2016
Q3 		$7K Sell
61
-7
-10% -$841 0.01% 333
2016
Q2 		$7K Hold
68
– – 0.01% 314
2016
Q1 		$8K Buy
68
+26
+62% +$3.29K 0.01% 314
2015
Q4 		$7K Hold
42
– – 0.01% 334
2015
Q3 		$6K Sell
42
-15,264
-100% -$2.45M ﹤0.01% 356
2015
Q2 		$2.66M Hold
15,306
– – 1.95% 18
2015
Q1 		$2.64M Hold
15,306
– – 1.98% 18
2014
Q4 		$1.98M Buy
15,306
+15,264
+36,343% +$1.97M 1.6% 28
2014
Q3 		$5K Sell
42
-20
-32% -$2.06K ﹤0.01% 379
2014
Q2 		$5K Buy
62
+10
+19% +$962 ﹤0.01% 390
2014
Q1 		$5K Hold
52
– – ﹤0.01% 390
2013
Q4 		$6K Hold
52
– – 0.01% 359
2013
Q3 		$4K Sell
52
-8
-13% -$585 ﹤0.01% 421
2013
Q2 		$4K Buy
+60
New +$3.87K ﹤0.01% 417

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Weaver C. Barksdale & Associates's UTHR Position: Q4 2017 in Review

Weaver C. Barksdale & Associates reduced its United Therapeutics (UTHR) stake by 4.2% in Q4 2017, selling an estimated $381 and leaving 68 shares worth $10K. The position accounts for 0.01% of the portfolio, ranked #279.

Weaver C. Barksdale & Associates first reported a position in UTHR in Q2 2013 and has held it in 19 quarters since. The position peaked at $2.66M in Q2 2015. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • Weaver C. Barksdale & Associates held 68 shares of United Therapeutics worth $10K as of Q4 2017.
  • Weaver C. Barksdale & Associates sold 3 United Therapeutics shares in Q4 2017, an estimated $381.
  • United Therapeutics made up 0.01% of Weaver C. Barksdale & Associates's portfolio in Q4 2017, its #279 holding.
  • Weaver C. Barksdale & Associates first reported a position in United Therapeutics in Q2 2013 and has held it in 19 quarters since.
  • Weaver C. Barksdale & Associates's United Therapeutics position peaked at $2.66M in Q2 2015.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.